Ranbaxy Laboratories launches generic Cadeut in the American market

NEW DELHI: Drug firm Ranbaxy Laboratories on Tuesday launched a generic version of Caduet, used for treating cardio vascular diseases, in the US market, as part of an agreement with Pfizer Inc.

The company's wholly-owned subsidiary Ranbaxy Pharmaceuticals Inc has launched generic Caduet indicated for patients suffering from both high-blood pressure and high levels of cholesterol, Ranbaxy said in a statement.

The Gurgaon-based firm, however, did not disclose the terms of the agreement with Pfizer.

Ranbaxy Senior Vice President and Regional Director Americas Venkat Krishnan said: "Atorvastatin-Amlodipine besylate tablet is a significant and important addition to our portfolio of cardio-vascular products, in the US."

Caduet presently marketed by Pfizer is a fixed-dose combination of Atorvastatin-Amlodipine besylate which also contains a crystalline form of Atorvastatin, Ranbaxy said.

According to IMS-MAT September 2011, Caduet generated total annual sales of USD 339 million in the US, it added.

The company is making available the full range of the generic version of Caduet, the company said.

Ranbaxy Laboratories, last week launched a generic version of blockbuster cholesterol-lowering drug Lipitor, which is also a Pfizer brand, in the US market.

Ranbaxy, a part of the Daiichi Sankyo Group, has presence in 125 countries with operations in 46 countries.